- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02128828
Effect of Cenicriviroc on HIV Neurocognitive Impairment
H020: Single-Arm Open Label, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HIV-associated neurocognitive disease (HAND), particularly in its milder form, is estimated to occur in greater than 30% of HIV infected individuals in the era of potent antiretroviral therapy. As even mild disease leads to functional consequences with decreased ability to live independently, HAND is of substantial public health concern. HIV-induced immune activation/inflammation of monocytes (MO) may be primarily responsible for the development of HAND.
Cenicriviroc is a combined CCR5 and CCR2 chemokine co-receptor antagonist. The investigators hypothesize that dual CCR5 and CCR2 blockade with the use of CVC will lead to measurable reductions in MO activation and lead to cognitive improvement by decreasing HIV infection of MO and by interrupting the trafficking of such MO into the central nervous system.
The investigators propose a single arm, 24-week trial of CVC in 24 subjects with HIV-1 infection suppressed on ART (plasma HIV RNA < 50 copies/ml) for 1 year or more with mild to moderate cognitive impairment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Clint Spencer Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 4.2.1.1 Documentation of HIV-1 infection by an FDA approved test at any time prior to study entry
- On ARV medication uninterrupted for > 1 year leading up to the screening period
- Screening plasma HIV RNA < 50 copies/ml within 3 months of entry
- Willingness for males and females of childbearing potential to utilize 2 effective contraception methods (2 separate forms, one of which must be an effective barrier method), be non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment and for 30 days following the last dose of study drugs.
- Age 18 to 70 years
- Ability and willingness to provide written informed consent
- Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal) score of < -0.5 or a neurocognitive abnormality (<-0.5) in at least one cognitive domain known to be typically affected by HIV OR unimpaired
- On antiretroviral (ARV) therapy consisting of nucleoside reverse transcriptase inhibitors, atazanavir with/or without ritonavir, darunavir plus ritonavir, dolutegravir, raltegravir or efavirenz.
Exclusion Criteria:
- Receiving or used a CCR5 antagonist within 6 months of study entry
- Plasma HIV RNA > 100 copies/ml within 6 mo. of screening
- HIV-2
- Chronic hepatitis B (positive hepatitis B surface antigen)
- Chronic hepatitis C (positive hepatitis C antibody), except with proof of viral clearance and normal liver function tests
- Active or chronic liver disease
- Active or inadequately treated tuberculosis infection, or inadequate treatment for a positive purified protein derivative test. Adequate treatment meets current recommendations of the Center for Disease Control, NIH and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA) guidelines or other Center for Disease Control recommendations if patient was treated before the current recommendations or before coinfection with HIV.
- Prior/current diagnosis with other intracellular pathogens (Listeria monocytogenes, Toxoplasma gondii, and Cryptococcus neoformans).
- Uncontrolled seizures
- Current or past malignancies excluding basal cell cancer and Kaposi's sarcoma (skin).
- Immunomodulator, HIV vaccine, any other vaccine, or investigational therapy within 30 days of entry.
- Requirement for acute therapy for AIDS-defining or other serious medical illnesses within 14 days of entry.
- Other chronic illnesses including hematologic, pulmonary, autoimmune diseases and endocrinopathies, except for stable controlled diabetes or cardiovascular disease in the view of the investigator and stable testosterone or thyroid therapy.
- Known hypersensitivity to CVC or its excipients
- Anticipated need for prescription medication not allowed in the study. Unwilling to stop eating grapefruit or using St. John's wort).
- Chronic use of over the counter medications unless approved by Study Investigator
- Hemoglobin < 8.5; Absolute neutrophil count < 1000; Platelet count < 100,000; serum glutamate oxaloacetate and pyruvate transaminase > 2.5x upper limit of normal ; Lipase > 2.0 x upper limit of normal
- Estimated creatinine clearance < 30 mL/min(Cockcroft and Gault 1979)
- Bradycardia, sinus rhythm <50 beats/min (bpm).
- Presence of any condition that would interfere with the absorption, distribution, metabolism, or excretion of the drug
- Current active illicit substance or alcohol use or abuse which, in the judgment of the Investigator, will interfere with the patient's ability to comply with protocol requirements
- Pregnancy or breast-feeding
- History of moderate (Child-Pugh class B) or severe (Child-Pugh C) hepatic impairment
- Patients, who, in the opinion of the Investigator, are unable to comply with the dosing schedule and protocol evaluation or for whom the study may not be advisable
- For MRI substudy [impaired]: Any factor that precludes MRI scan including presence of metal or exposure to metal work (e.g. metal grinder/worker) and claustrophobia
- For MRI substudy [impaired]: Any central nervous system pathology which, in the judgment of the investigator, will interfere with the ability to assess study change in magnetic resonance spectroscopy
- 4.2.2.28 For lumbar puncture substudy: Thrombocytopenia or other bleeding disorders (including ongoing anticoagulant therapy), suspected increased intracranial pressure or spinal epidural abscess, or any other factor which would increase risk of complications following lumbar puncture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: cenicriviroc
cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
|
cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 24 in Global Neuropsychological Performance
Time Frame: baseline, week 24
|
Raw scores from individual performance on 14 validated neuropsychological tests meant to assess various cognitive domains were converted into standardized z-scores adjusted for age, sex, and education.
Z-scores from all tests were aggregated and averaged to determine each subject's Global Neuropsychological Performance Score; NPZ-Global).
Z-scores follow a normal distribution with scores < '0' identifying poorer cognition than 'average' and scores > "0" identifying better cognition than average with -1 and +1 represented 1 SD below or higher than average.
|
baseline, week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Cecilia Shikuma, MD, University of Hawaii - Hawaii Center for AIDS (HICFA)
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Neurocognitive Disorders
- Slow Virus Diseases
- HIV Infections
- Dementia
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- AIDS Dementia Complex
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- CCR5 Receptor Antagonists
- Cenicriviroc
Other Study ID Numbers
- H020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AIDS Dementia Complex
-
University Hospital, Basel, SwitzerlandTerminatedAIDS-related Dementia ComplexSwitzerland
-
National Institute of Mental Health (NIMH)TerminatedHIV Infections | Healthy | AIDS Dementia Complex | AIDS-Related Dementia Complex | HIV-Associated Cognitive Motor Complex | HIV-Dementia | AIDS EncephalopathyUnited States
-
Centre Hospitalier Universitaire Saint PierreFonds iris-Recherche, Fondation Roi Baudouin, BelgiumCompletedAIDS-Related Dementia ComplexBelgium
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)CompletedHIV Associated Cognitive Motor ComplexUnited States
-
National Institutes of Health Clinical Center (CC)CompletedDepression | HIV Infections | HIV-Associated Cognitive Motor ComplexUnited States
-
Holdsworth House Medical PracticeCompletedHIV-1-Associated Cognitive Motor Complex
-
National Institute of Mental Health (NIMH)TerminatedHIV-Associated Cognitive Motor ComplexUnited States
-
University of California, Los AngelesUnknown
-
Universidad Nacional Autonoma de MexicoRecruitingTelerehabilitation | Neuropsychology | HIV DementiaMexico
Clinical Trials on cenicriviroc
-
Charite University, Berlin, GermanyAllerganTerminated
-
Tobira Therapeutics, Inc.CompletedType 2 Diabetes Mellitus | Prediabetic State | Non-alcoholic Fatty Liver DiseaseUnited States, Puerto Rico
-
Tobira Therapeutics, Inc.CompletedLiver InsufficiencyUnited States
-
National Institute of Allergy and Infectious Diseases...AllerganWithdrawn
-
Novartis PharmaceuticalsAllerganCompletedNon-alcoholic Steatohepatitis (NASH)United States, Belgium, Spain, Canada, Argentina, Israel, Germany, France, Italy, Turkey, Singapore, Russian Federation, United Kingdom, Czechia, Egypt, India, Latvia
-
Tobira Therapeutics, Inc.CompletedPrimary Sclerosing CholangitisUnited States, Canada
-
Tobira Therapeutics, Inc.Completed
-
Tobira Therapeutics, Inc.CompletedNonalcoholic SteatohepatitisBelgium, Spain, Hong Kong, United States, France, Germany, Australia, United Kingdom, Poland, Italy
-
AllerganCompletedHepatic ImpairmentUnited States
-
Tobira Therapeutics, Inc.TerminatedNonalcoholic SteatohepatitisUnited States, Spain, Australia, Belgium, Israel, Canada, Puerto Rico, Italy, Germany, France, New Zealand, Taiwan, Poland, United Kingdom, Brazil, Austria, Singapore, Portugal, Chile, Greece, Hong Kong, Hungary, Latvia, Mexico, Norway, R... and more